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Abstract: Colorectal adenocarcinoma is one of the most prevalent malignancies 
worldwide. The presence of regional lymph node metastases is an important 
prognostic indicator in colorectal adenocarcinoma. CD44 is a transmembrane protein 
and a cancer stem cell biomarker that plays a role in tumor proliferation, metastasis, 
and recurrence. The tumor microenvironment has a vital role in the stage of tumor 
development. CD8 is one of microenvironment's component which kills the tumor cells. 
This study aimed to analyze the expression of CD44 and CD8 and investigated their 
association with colorectal adenocarcinoma metastatic. This study's benefit is that the 
resulting study can be used as a prognostic factor in colorectal adenocarcinoma. This 
study included 56 paraffin blocks of patients diagnosed as colorectal adenocarcinoma 
during January 2017-December 2018 in Anatomic Pathology Laboratory  Dr. Soetomo 
Hospital Surabaya. The paraffin blocks were sliced and stained with 
immunohistochemistry for CD44 and CD8. The parameters were a positive percentage 
of tumor cell and lymphocyte immunoreactivity against CD44 and CD8 antibodies. The 
percentage of CD44 is higher in the metastatic group, and the percentage of CD8 is 
higher in the non-metastatic group. There was a significant negative correlation 
between CD44 and CD8 expression in regional lymph nodes metastatic. These results 
indicated that CD44 and CD8 have a vital role in the incidence of metastasis. 
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INTRODUCTION 
 Colorectal carcinoma is the third most common malignancy globally, with an 
increased incidence in the elderly. Every year, colorectal carcinoma is diagnosed by 
more than 940,000 people, and around 500,000 people die from this cancer (Holah et 
al., 2017). It estimated that there are 1.23 million new cases globally, which is about 
9.7% of all new cases of malignancy. This malignancy is placed third in males after 
lung, prostate, and gastric malignancies (Hamilton et al., 2010; Rawla et al., 2019). 
The data gathered in the Anatomy Pathology laboratory Dr. Soetomo Surabaya 
show an increase in the number of new diagnoses of colorectal carcinoma cases each 
year, namely 104 cases in 2012, 143 cases 2013, and then 169 cases in 2014.  
The role of cancer stem cells within tumor development began to be widely 
studied; CD44 is a marker of stem cells in colorectal adenocarcinoma. CD44 is a 
transmembrane protein which is also part of cell adhesion molecules that plays a role 
in cell-to-cell communication and interactions with the extracellular matrix and has a 
role in tumor development, proliferation, and metastasis in which affect the prognosis 
and survival (Chen et al., 2018; Holah et al., 2017). 
Cancer stem cells are characterized by their resistance to anti-cancer therapy 
and trigger tumor metastases and recurrence. Radiation and chemotherapy can 
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currently kill most cancer cells but often do not eliminate cancer stem cells protected 
by specific resistance mechanisms (Magee et al., 2012). 
CD44 is a transmembrane glycoprotein. The expression of CD44 is also 
regulated in the sub-population of cancer cells. It is recognized as a molecular marker 
for cancer stem cells, one of which is in colon cancer (Chen et al., 2018). Previous 
studies have shown that CD44 expression can be influenced by the degree of 
differentiation. A low degree of differentiation indicates that a positive CD44 
percentage will be higher. Likewise, with its expression related to lymph node 
metastasis, high CD44 expression has a worse prognosis (Ma et al., 2019; Zhao et 
al., 2015). 
The tumor cells' ability to express CD44 to metastasize is influenced by the 
micro-environment around the tumor, including stromal cells, extracellular matrix, 
blood vessels, and immune cells. Immune cells are one part of the micro-environment. 
One of the immune cells that play a role in tumor development is CD8, which functions 
as a cytotoxic T lymphocyte (CTL) that will kill tumor cells. The low density of CD8 will 
affect the risk of recurrence, metastasis, and survival in colorectal adenocarcinoma 
(de Vries et al., 2016).In previous research shows that there is a correlation between 
high frequency of CD8 positive lymphocyte infiltration and lack of lymph node 
involvement in rectal cancer (Daster et al., 2014).  
 Previous research involving these two markers has not been conducted. Thus, 
this research is vital to comprehend the role of both markers in the metastatic process 
in colorectal adenocarcinoma. 
 
MATERIALS AND METHOD 
This study had approved by the Health Research Ethics Committee of Dr. 
Soetomo General Hospital, Surabaya (Ethical Clearance no. 1561/KEPK/X/2019). 
This study was an analytic observational study with a cross-sectional approach, using 
paraffin-embedded from the operating tissue of patients with colorectal 
adenocarcinoma, which were established based on histopathological features in the 
Anatomical Pathology Installation of Dr. Soetomo Surabaya period January 2017 - 
December 2018. The total sample of 56 samples consisted of 2 groups, namely 
colorectal adenocarcinoma with regional lymph node metastases and colorectal 
adenocarcinoma without regional lymph node metastases. Thus, the total sample of 
each group was 28 paraffin-embedded. 
This tissue was cut into 4µm sections, deparaffinized three times with xylol for 
5 minutes each, and rehydrated through graded alcohol. Antigen retrieval was 
achieved by microwave treatment in sodium citrate buffer (pH 6,0) for 10 minutes. 
These tissue sections were then incubated with monoclonal antibodies for HCAM 
(DF1485: sc-53534; dilution 1:250; Santa Cruz Biotechnology) and CD8 (4B11; 
dilution 1:50; Leica Biosystems) followed by the secondary antibody for 10 minutes at 
room temperature. The section was then counterstained with hematoxylin and 
dehydrated with alcohol.  
The study used CD44 and CD8 immunohistochemistry in adenocarcinoma 
colorectal paraffin blocks with and without regional lymph node metastases. CD44 was 
examined with which was positively stained on the membrane and cytoplasm of tumor 
cells. CD8 was examined with which was positively stained on the lymphocyte cell 
membrane. 
CD44 expression was assessed by calculating the mean percentage in the five 
densest fields of view by dividing the number of tumor cells stained brown on the 
membrane and cytoplasm by the number of tumor cells in the field of view. 
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%CD44 (one field of view) = number of tumor cells stained brown X 100% 
                                                          Total number of tumor cells  
 
Assessment of CD8 expression in each sample group was done by calculating 
the mean percentage in the five densest fields of view by dividing the number of 
lymphocyte cells stained brown on the membrane by the number of lymphocyte cells 
in that field of view. 
 
%CD8 (one field of view) = number of lymphocyte cells stained brown X 100% 
                                                       Total number of lymphocyte cells 
  
RESULTS AND DISCUSSION 
Data analysis used to determine differences in CD44 and CD8 expression with 
regional lymph node metastasis status in colorectal adenocarcinoma is an 
independent T-test. To find out the correlation between CD44 and CD8, the study uses 
the Pearson correlation test. The statistical test was significant if p<0.05.  
CD44 expression in this study is reflected in the membrane and cytoplasm of 
tumor cells (Figure 1). The data obtained from this study showed that the mean CD44 
expression in the metastatic group was 61.8±26.7, while in the non-metastatic group, 
it was 41.8±27.4. The differences between the two groups were then analyzed using 
an independent T-test. The statistical analysis results showed a significant difference 
between CD44 expression in colorectal adenocarcinoma with metastases and without 
regional lymph node metastases with p=0,008 (p<0.05). These data showed a higher 
expression of CD44 in colorectal adenocarcinoma with metastases than without 
regional lymph node metastases (Table 1). 
The correlation between CD44 expression and colorectal adenocarcinoma 
metastatic status statistically tested using the Spearman correlation test. The analysis 
showed a significant correlation where the Spearman correlation coefficient was 0.348 
with p=0.003 (p<0.05). These results indicate that the higher the expression of CD44 
is in line with the increase in regional lymph node metastasis status (Table 2). 
 
 
Figure 1. Expression of CD44 on Colorectal Adenocarcinoma Tumor Cells.CD44 
Streaked Brown on the Membrane and Cytoplasm of Tumor Cells Magnification 200x 
 
Table 1. CD44 Expression in Colorectal Adenocarcinomas 
 
Metastatic status Mean SD Min Maks p 
Metastatic 61,8 26,7 6,57 91,72 0,008 
Non-metastatic 41,8 27,4 2 90,69  
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CD8 expression in this study was reflected in the lymphocyte cell membrane 
(Figure 2). This study showed that the mean CD8 expression in the metastatic group 
was 30.8±13.1, while the non-metastatic group was 45.3±11.9. The differences 
between the two groups were then analyzed using an independent T-test. The 
statistical analysis results showed a significant difference between CD8 expression in 
colorectal adenocarcinoma with metastases and without regional lymph node 
metastases with p=0,01 (p<0.05). These data showed that CD8 expression in 
colorectal adenocarcinoma with metastases is lower than its expression in the area 
without regional lymph node metastases (Table 3). 
The correlation between CD8 expression and metastatic status in colorectal 
adenocarcinoma statistically tested using the Spearman correlation test. The analysis 
showed a significant correlation where the Spearman correlation coefficient was -
0.544 with p=0.001 (p<0.05). These results indicate that the higher the expression of 
CD8 is in line with the decrease in the metastatic status of regional colorectal 
adenocarcinoma lymph nodes (Table 4). 
 The Pearson correlation test results showed a significant relationship between 
CD8 and the metastatic status of regional lymph nodes (p=0.001) with a correlation 
coefficient of -0.508. These results indicate that the higher CD8 expression is in line 
with the decreased status of regional lymph node metastases.  
 
 
Figure 2. CD8 Expression in Colorectal Adenocarcinoma. CD8 was Streaked Brown 
in 70% of the Lymphocyte Cell Membrane within Tumor Cells. 400x Magnification 
 
Table 3. CD8 Expression in Colorectal Adenocarcinomas 
 
Metastatic status Mean SD Min Maks p 
Metastatic 30,8 13,1 4,77 60,37 0,001 
Non-metastatic 45,3 11,9 4,1 60,94  
 
  CD44 expression 
Metastatic status rs 0,348 
 p 0,003 
n 56 
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The correlation between CD44 and CD8 expression in colorectal 
adenocarcinoma with and without regional lymph node metastases statistically tested 
using the Pearson correlation test. The analysis showed that there was a significant 
correlation where the Pearson correlation coefficient was -0.316 with a p-value=0.018 
(p<0.05), which means that the higher the CD44 expression, the lower the CD8 
expression (Table 5). 
 
Tabel 5. Correlation CD44 and CD8 Expressions 
 
  CD8 expression 
CD44 expression r -0,316 
 p 0,018 
 r 56 
 
This study's results are consistent with several previous studies, which stated 
a significant correlation between CD44 expression and lymph node metastasis status 
in colonic adenocarcinoma, a higher CD44 expression obtained in tumor cells with 
lymph node metastasis (Holah et al., 2016). Research by Zhao et al. also showed a 
correlation of CD44 expression with lymph node metastasis and TNM stage in 
colorectal carcinoma, where the higher stage N showed higher CD44 expression in 
primary tumors (Zhao et al., 2015).  
Another study conducted by Li et al. looked at the expression of CD44 with 
CD44 variant exon 6, where there was a significant relationship between both 
expression and lymph node metastasis, degree of differentiation, stage of Dukes, and 
survival rate of 5 years. This study shows that colorectal carcinoma patients with high 
CD44 have a 5-year life expectancy of 52.78%, while those with negative CD44 show 
a better life expectancy of 80.9% (Li et al., 2013; Ma et al., 2019). Another study on 
breast carcinoma by Ma and Jiang showed a higher CD44 expression in breast 
carcinomas with lymph node metastases than without metastases (Ma and Jiang, 
2013). 
Several previous studies have shown different results that high CD44 
expression is not associated with the incidence of lymph node metastasis and shows 
better expression in colorectal carcinoma (Du et al., 2008). Research by Chen et al. 
showed no significant relationship between CD44 expression and grade, stage, and 
prognosis (Chen et al., 2011). The difference in this study results could be due to 
differences in the isoform variant of CD44 and also influenced by its binding to the 
extracellular matrix components (Ma et al. 2019). Other factors can be due to 
differences in the type of antibody, the number of samples, the staining process, and 
immunohistochemical reporting (Chaitra et al., 2018). 
The role of CD44 in cancer progression is influenced by the microenvironment 
around the tumor, including immune cells, fibroblasts, vascular endothelial cells, 
extracellular matrix components, and various cytokines and chemokines. Various 
  CD8 expression 
Metastatic status rs -0,544 
 p 0,001 
n 56 
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cytokines that affect the action of CD44 include IL-8, G-CSF which play a role in tumor 
proliferation, angiogenesis, and metastasis, and TGF-β, which is involved in the EMT 
mechanism associated with tumor cell invasion and metastasis. One of the chemokine 
molecules that affect the action of CD44 is CXCL12. The interaction between CXCL12 
and CXCR4 will affect the role of CD44 in metastasis of colorectal carcinoma. 
Inhibition of the CXCL12-CXCR4 interaction will reduce the expression of CD44 in 
tumor cells (Chen et al., 2018; Ma et al., 2019). CD44 through CXCR4 can also affect 
the immune system around tumor cells. CXCR4 protein will attract dendritic cells to 
come into the environment around the tumor. Dendritic cells can suppress anti-tumor 
immunity through cytotoxic T-lymphocytes inactivation(Xu et al., 2015). 
CD44 is a receptor located in the cell membrane, which then binds with 
hyaluronan acid (HA) as a ligand located on the extracellular matrix (Chen et al., 2018). 
The interaction between CD44 and HA modifies the extracellular matrix component 
(ECM) to trigger tumor cell invasion by stimulating the production of MMP2 and MMP9. 
Furthermore, MMP2 can degrade type IV collagen as the main component that forms 
the structure of cell membranes. If the barrier can be passed, the tumor cells will 
develop metastasis to lymph nodes and distant organs. MMP9 can also trigger 
metastasis by triggering TGFβ activity through interactions with CD44. TGFβ / SMAD 
signals induce EMT so that metastases can occur (Ma et al., 2019).  
The role of CD44 in cancer progression is influenced by the micro-environment 
surrounding the tumor, including immune cells, fibroblasts, vascular endothelial cells, 
extracellular matrix components, and various cytokines and chemokines [29]. Various 
cytokines that affect the work of CD44 include IL-8, G-CSF, which role is affecting 
tumor proliferation, angiogenesis, and metastasis, and also TGF-β, which participate 
in the EMT mechanism associated with invasion and metastasis of tumor cells. One 
chemokine molecule that affects CD44's action is CXCL12 (Ma et al., 2019). 
Cytotoxic T Lymphocytes (CTL) are lymphocytes that can induce damage and 
kill infected cells or tumor cells (Abbas et al., 2015). CD8 (Cluster of Differentiation 8) 
is a glycoprotein that functions as a co-receptor for T Cell Receptors, mainly expressed 
on cytotoxic T-cells' surface. Some studies state that the infiltration of CD8+ T cells in 
tumors and their environment will provide a better prognosis (Barnes & Amir, 2017; 
West et al., 2015; Ziai et al., 2018). The infiltration of CD8+ T cells in tumors itself 
happens at the intertumoral location (between tumor cells) or stromal (between tissues 
and blood vessels around the tumor) (Ziai et al., 2018). 
Immune cells are part of the tumor microenvironment, which influences the 
development of tumor cells. CD8+ T-cells are a component of immune cells that cause 
tumor cells' death through an apoptotic mechanism by releasing granzymes and 
perforin (Barnes and Amir., 2017; Jackute et al., 2015). 
A study by Idos et al. demonstrated an association between CD8+ T lymphocytes' 
presence and the survival of colorectal cancer patients. The high number and density 
of CD8+ T-lymphocytes have better survival (Idos et al., 2020). 
Research conducted by West et al. examined that the presence of CD8+ is 
associated with improved patient life expectancy compared to low infiltration from 
CD8+. This condition depends on the number of cytotoxic T cells in primary tumors 
associated with reduced likelihood of metastasis and increasing life expectancy of 
colorectal cancer patients (Iseki et al., 2018; West et al., 2015). 
A study conducted by Kedr et al. stated that a significant decrease in CD8+ T 
cell was associated with a poor prognosis with increased tumor development and 
metastatic events (Khedr et al., 2016). 
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The literature reviews show that differences in mutation loads cause differences 
in CD8 expression in colorectal carcinoma. These high mutation loads can produce 
high antigenicity by regulating antigens recognized by the immune system. Colorectal 
carcinomas with MSI phenotype show increased immunogenicity compared to 
colorectal carcinomas with MSS mutations. This is indicated by the presence of more 
dominant CD8+ cytotoxic T cells found in colorectal carcinomas with higher 
immunogenicity (de Vries et al., 2016). 
This study found a significant negative correlation between CD44 expression 
and CD8 expression in colorectal adenocarcinoma. Considering some studies, CD44 
expression positively correlates with FOXP3, where FOXP3 is one of the T regulator 
markers. T regulator is an immunosuppressive whose function is to regulate the 
immune reaction's balance and maintain tolerance of the antigen itself. In certain 
circumstances, T reg will suppress the ability of CD8 cytotoxic T cells against tumor 
cells. This situation involves TGFβ and IL10 (Chen et al., 2005; Peng et al., 2019). 
The immune response is a very complex system, and it is difficult to explain 
how many immune factors greatly influence the presence of stem cells and cancer 
cells. The initial phase is the elimination phase, where the innate and adaptive immune 
systems work to destroy cancer cells. This requires a balance of anti-tumor immune 
responses such as CD8 T cells, CD4 T cells, and NK cells. In the equilibrium phase, 
there is a balance between anti-tumor and pro-tumor factors with CD8 selection, where 
T reg plays a role in inhibiting APC, CD8, NK cells, and CD4 cells. This process will 
inhibit recognition and destruction by immune cells so that carcinoma cells will be 
released and develop in the final phase. In a continuous and prolonged activity, CD8 
T cells will experience fatigue, then CTLA-4 and PD1 on CD8 will provide inhibitory 
signals that cause a decrease in CD8 (Dushyanthen et al., 2015). 
The body's immune response can have anti-tumor and pro-tumor roles. Tumor 
cells, in this case, cancer stem cells, will activate macrophages by releasing IL-10. 
Macrophages have a role in adaptive immunity by producing cytokines, namely IL-1, 
which triggers Th1 to produce IFNγ (Abbas et al., 2015). Effective anti-tumor immunity 
is thought to be driven mainly by interferon-γ (IFNγ). Dendritic cells express 
costimulatory molecules and inflammatory cytokines such as IL-12, IL-23, and IL-1 
that trigger the response of CD4+ T cells secreting IFNγ and cytotoxic T lymphocytes 
(Wang et al. 2017). 
CD4+ T-cells can recognize and bind to MHC II on APC, while CD8+ with MHC 
I, which plays a role in tumor cells' death through apoptosis by releasing granzyme 
and perforin. NK cells, with the help of APC and CD4+, are also able to recognize and 
eliminate tumor cells. CTL's role in killing tumor cells is often not able to eliminate the 
cancer stem cells so that they can continue to develop and the occurrence of 
metastases (Magee et al., 2012). NK cells recognize molecules expressed by tumor 
cells and will be activated if the target cells do not have MHC class I molecules. 
Therefore NK cells have a mechanism to kill - negative MHC class I (class I MHC-
negative tumors) (Abbas et al., 2015). 
TAM influences the process of migration and metastasis through the 
extracellular matrix. TAM produces proteases and Matrix Metalloproteinase (MMP), 
which cause degradation of ECM and basement membrane. Besides, the presence of 
epithelial-mesenchymal transition (EMT) has a role in metastasis, resulting from the 
interaction of tumor cells with TAM. TAM also plays a role in forming a premetastatic 
niche (Yang et al., 2017). 
Colorectal carcinoma with the MSI phenotype showed more CD8+ cytotoxic T 
lymphocyte (CTL) infiltration. CTL induces cancer cell death by relying on the bonds 
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between the Fas-Fas ligands. CTL expresses ligands so that Fas on the surface of 
tumor cells will bind to ligands on CTL to undergo apoptosis. The CD44 molecule 
functions to bind Fas to prevent the interaction between Fas and Fas ligands (Ma et 
al., 2019). 
 This study indicates that an increase in CD44 expression in tumor cells and a 
decrease in CD8 expression in lymphocytes around the tumor are associated with an 
increased incidence of metastases in colorectal adenocarcinoma. This research is 
expected to be useful as a prognostic, predictive factor, and progression of colorectal 
cancer and subsequent immunotherapy development. This study's drawback is that 
the data used are limited to tumor cells with regional lymph node metastases only, not 
examining distant organ metastases. 
 
CONCLUSION 
 The expression of CD44 and CD8 is an important marker for determining the 
incidence of metastasis in colorectal carcinoma to be used as a prognostic factor for 
cancer development. This research can be used as a reference for future research 
regarding the role of cancer stem cells and microenvironment components. 
 
ACKNOWLEDGMENT 
 The authors thanks Budi Utomo, MD from Department of Community Medicine 
for sharing statistical aspect of this study. The authors also acknowledge all of lectures 
in Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga for 
the guidance in finishing this study.  
 
CONFLICT OF INTEREST 
 The authors have no conflict of interest to disclose. 
 
REFERENCE 
Abbas, A. K. Lichtman, A. H. Pillai, S. (2015) Basic immunology, functions and 
disorders of the immune system (5th ed), Elsevier. pp. 218-223. 
Barnes, T.A., & Amir, E. (2017). HYPE or HOPE: the prognostic value of infiltrating 
immune cells in cancer. British Journal of Cancer, 117(4), 451–460. 
https://doi.org/10.1038/bjc.2017.220 
Chaitra, L. P., Prashant, A., Gowthami, C. S., Hajira, B., Suma, M. N., Mahesh, S. S., 
Manjunath, G. V., & Sheeladevi, C. S. (2019). Detection of cancer stem cell-
related markers in different stages of colorectal carcinoma patients of Indian 
origin by immunohistochemistry. Journal of cancer research and 
therapeutics, 15(1), 75–81. https://doi.org/10.4103/jcrt.JCRT_991_16 
Charan, J., & Biswas, T. (2013). How to calculate sample size for different study 
designs in medical research?. Indian Journal of Psychological Medicine, 35(2), 
121–126. https://doi.org/10.4103/0253-7176.116232 
Chen, C. Zhao, S. Karnad, A & Freeman, J. W. (2018). The biology and role of CD44 
in cancer progression : therapeutic implication. Journal of Hematology, 11(64), 
1-23. doi: 10.1186/s13045-018-0605-5. 
Chen, M. L., Pittet, M. J., Gorelik, L., Flavell, R. A., Weissleder, R., von Boehmer, H., 
& Khazaie, K. (2005). Regulatory T cells suppress tumor-specific CD8 T cell 
cytotoxicity through TGF-beta signals in vivo. Proceedings of the National 
Academy of Sciences of the United States of America, 102(2), 419–424. 
https://doi.org/10.1073/pnas.0408197102 
P a g e  | 143 
 
Copyright © 2020, MLTJ, ISSN 2461-0879 
 
Cho, J., Chang, Y. H., Heo, Y. J., Kim, S., Kim, N. K., Park, J. O., Kang, W. K., Lee, 
J., & Kim, K. M. (2018). Four distinct immune microenvironment subtypes in 
gastric adenocarcinoma with special reference to microsatellite instability. ESMO 
open, 3(3), e000326. https://doi.org/10.1136/esmoopen-2018-000326 
Chu, P. G. dan Weiss, L. M. (2009) ‘ Modern immunohistochemistry’, Cambridge 
Illustrated Surgical Pathology, pp. 489-490. 
Daster, S., Eppenberger-Castori, S., Hirt, C., Zlobec, I., Delko, T., Nebiker, C. A., 
Soysal, S. D., Amicarella, F., Iezzi, G., Sconocchia, G., Heberer, M., Lugli, A., 
Spagnoli, G. C., Kettelhack, C., Terracciano, L., Oertli, D., von Holzen, U., 
Tornillo, L., & Droeser, R. A. (2014). High frequency of CD8 positive lymphocyte 
infiltration correlates with lack of lymph node involvement in early rectal 
cancer. Disease markers, 2014, 792183. https://doi.org/10.1155/2014/792183 
de Vries, N. L., Swets, M., Vahrmeijer, A. L., Hokland, M., & Kuppen, P. J. (2016). The 
immunogenicity of colorectal cancer in relation to tumor development and 
treatment. International Journal of Molecular Sciences, 17(7), 1030. 
https://doi.org/10.3390/ijms17071030 
Du, L., Wang, H., He, L., Zhang, J., Ni, B., Wang, X., Jin, H., Cahuzac, N., Mehrpour, 
M., Lu, Y., & Chen, Q. (2008). CD44 is of functional importance for colorectal 
cancer stem cells. Clinical cancer research : an official journal of the American 
Association for Cancer Research, 14(21), 6751–6760. doi:10.1158/1078-
0432.CCR-08-1034. 
Dushyanthen, S., Beavis, P. A., Savas, P., Teo, Z. L., Zhou, C., Mansour, M., Darcy, 
P. K., & Loi, S. (2015). Relevance of tumor-infiltrating lymphocytes in breast 
cancer. BMC Medicine, 13, 202. https://doi.org/10.1186/s12916-015-0431-3 
Hamilton, S. R., Bosman, F. T.,  Boffeta, P., Ilyas, M., Morreau, H., Nakamur, S. I., 
Quirke, P., Riboli, E., Sobin, L. H. (2010) WHO classification of tumours of the 
digestive system(4th ed). Lyon: IARC Press, pp. 131-146. 
Holah, N. S., Aaid, H. A., Assad, N. Y., Elkhouly, E. A., & Lasheen, A. G., (2017) 
Evaluation of the role of CD44 as a cancer stem cell marker in colorectal 
carcinoma: immunohistochemical study.Menoufia Medical Journal, 30, 174-183. 
doi: 10.4130/mmj. Mmj_151_16. 
Idos, G. E., Kwok, J., Bonthala, N., Kysh, L., Gruber, S. B., & Qu, C. (2020). The 
prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: a 
systematic review and meta-analysis. Scientific Reports, 10(1), 3360. 
https://doi.org/10.1038/s41598-020-60255-4 
Iseki, Y. Shibutani, M. Maeda, K. Nagahara, H. Fukuoka, T. Matsutani, S. Kashigawa, 
S. Tanaka, H. Hirakawa, K., & Ohira, M. (2018). Infiltrating Lymphocytes (TILs) 
in colorectal cancer using hematoxylin and eosis (HE)-stained tumor sections’, 
PLoS ONE, 13(4), 1-12. doi: 10.13/1/journal.pone.0192744. 
Jackute, J., Zemaitis, M., Pranys, D., Sitkauskiene, B., Miliauskas, S., Bajoriunas, V., 
Lavinskiene, S., & Sakalauskas, R. (2015). The prognostic influence of tumor 
infiltrating Foxp3(+)CD4(+), CD4(+) and CD8(+) T cells in resected non-small cell 
lung cancer. Journal of Inflammation, 12, 63. https://doi.org/10.1186/s12950-
015-0108-x 
Khedr, R.A.E, Ghannam A.A.E, El-Rahidy. M. A.,&El-Deen, A.A.S. (2016) The 
prognostic role of tumor infiltrating lymphocytes CD8 and FOXP3 and their 
impact on recurrence in breast cancer patients. Journal of Cancer Science & 
Therapy, 8(7), 206-212. doi:10.4172/1948-5956.1000414. 
P a g e  | 144 
 
Copyright © 2020, MLTJ, ISSN 2461-0879 
 
Ma, L., Dong, L., & Chang, P. (2019). CD44v6 engages in colorectal cancer 
progression. Cell Death & Disease, 10(1), 30. https://doi.org/10.1038/s41419-
018-1265-7 
Ma, L., Jiang, T. (2013). Clinical implications of Ezrin and CD44 co-expression on 
breast cancer. Oncology Reports, 30, 1899-1905 
Magee, J. A., Piskounova, E., & Morrison, S. J. (2012). Cancer stem cells: impact, 
heterogeneity, and uncertainty. Cancer Cell, 21(3), 283–296. 
https://doi.org/10.1016/j.ccr.2012.03.003 
Peng, G. L., Li, L., Guo, Y. W., Yu, P., Yin, X. J., Wang, S., & Liu, C. P. (2019). 
CD8+ cytotoxic and FoxP3+ regulatory T lymphocytes serve as prognostic factors 
in breast cancer. American Journal of Translational Research, 11(8), 5039–
5053. 
Rawla, P. Sunkara, T. Barsouk, A. (2019) Epidemiology of colorectal cancer: 
incidence, mortality, survival, and risk factors, Gastroenterology Review, 14(2), 
89-90. doi:105114/pg.2018.81072. 
Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, 
J., Cao, K., Li, X., Xiong, W., Li, G., Zeng, Z., & Guo, C. (2017). Role of tumor 
microenvironment in tumorigenesis. Journal of Cancer, 8(5), 761–773. 
https://doi.org/10.7150/jca.17648 
Wang, Z., Tang, Y., Xie, L., Huang, A., Xue, C., Gu, Z., Wang, K., & Zong, S. (2019). 
The prognostic and clinical value of CD44 in colorectal cancer: a meta-
analysis. Frontiers in Oncology, 9, 309. https://doi.org/10.3389/fonc.2019.00309 
West, N. R., McCuaig, S., Franchini, F., & Powrie, F. (2015). Emerging cytokine 
networks in colorectal cancer. Nature reviews. Immunology, 15(10), 615–629. 
https://doi.org/10.1038/nri3896 
Xu, C., Zhao, H., Chen, H., & Yao, Q. (2015). CXCR4 in breast cancer: oncogenic role 
and therapeutic targeting. Drug Design, Development and Therapy, 9, 4953–
4964. https://doi.org/10.2147/DDDT.S84932 
Yang, L., & Zhang, Y. (2017). Tumor-associated macrophages: from basic research 
to clinical application. Journal of Hematology &Oncology, 10(1), 58. 
https://doi.org/10.1186/s13045-017-0430-2 
Zhao, L. H., Lin, Q. L., Wei, J., Huai, Y. L., Wang, K. J., & Yan, H. Y. (2015). CD44v6 
expression in patients with stage II or stage III sporadic colorectal cancer is 
superior to CD44 expression for predicting progression. International Journal of 
Clinical and Experimental Pathology, 8(1), 692–701. 
Zhou, Y., Xia, L., Wang, H., Oyang, L., Su, M., Liu, Q., Lin, J., Tan, S., Tian, Y., Liao, 
Q., & Cao, D. (2017). Cancer stem cells in progression of colorectal 
cancer. Oncotarget, 9(70), 33403–33415. 
https://doi.org/10.18632/oncotarget.23607 
Ziai, J., Gilbert, H. N., Foreman, O., Eastham-Anderson, J., Chu, F., Huseni, M., & 
Kim, J. M. (2018). CD8+ T cell infiltration in breast and colon cancer: a histologic 
and statistical analysis. PloS One, 13(1), e0190158. 
https://doi.org/10.1371/journal.pone.0190158 
 
